The latest in policy & regulation: 3 developments from the past day, tracked and curated by the HealthTech Cube news desk. The lead story: Lupin receives tentative FDA approval for novel apixaban oral suspension.
Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder
Mirum Pharmaceuticals’ Atebrioz is the third FDA-approved drug for fibrodysplasia ossificans progressiva (FOP), but it brings advantages over the two other products for this rare disease that leads to bone growth in soft tissue. Mirum acquired Atebrioz from Incyte earlier this year. The post Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder appeared first on MedCity News.
Follow the full firehose on the HTC Wire, refreshed automatically every day.
Reach the people behind these stories. HealthTech Cube demand gen programs deliver qualified healthcare technology leads from $49.50 per lead - see packages or download the 2026 media kit.